Talc pleurodesis in malignant pleural effusion: a systematic review and meta-analysis

Abstract

Objective

Malignant pleural effusion is a severe and common complication in patients with primary or metastatic malignancies of the pleura. Although talc pleurodesis is widely used for managing malignant pleural effusions, there is still controversy in the literature regarding its superiority compared to other approaches. We conducted this meta-analysis to further investigate its efficacy compared to alternative interventions.

Methods

We systematically reviewed the PubMed, Cochrane, and Scopus databases to identify studies that fulfilled our inclusion criteria. Study quality was evaluated using validated tools and the pooled Risk Ratio (RR) and confidence interval (CI) were calculated. We performed sensitivity analyses based on the meta-analysis method and type of study.

Results

Twenty-four studies were included in the current systematic review meta-analysis. Talc pleurodesis was associated with statistically significant higher successful pleurodesis rates when compared with all controls [RR (95% CI) 1.15 (1.00, 1.31); Pz = 0.04], only chemical controls [RR (95% CI) 1.26 (1.13, 1.40); Pz < 0.0001], and bleomycin [RR (95% CI) 1.22 (1.05, 1.42); Pz = 0.008]. The comparison between talc pleurodesis and controls at the > 1-month follow-up time point favored talc pleurodesis [RR (95% CI): 1.62 (1.15, 2.27); Pz = 0.005]. Finally, talc poudrage was associated with a statistically significant higher successful pleurodesis rate when compared with all controls. Sensitivity analyses verified the robustness of our results.

Conclusion

Talc pleurodesis is an effective MPE management approach presenting borderline statistically significant superiority compared to control methods especially compared to bleomycin as well as when pleurodesis success is evaluated later than 1 month postoperatively.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. 1.

    Yeung M, Loh E-W, Tiong T-Y, Tam K-W. Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis. Clin Exp Metas. 2020;37(4):541–9.

    Article  Google Scholar 

  2. 2.

    Bibby AC, Dorn P, Psallidas I, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg. 2019;55(1):116–32.

    PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Keshishyan S, Harris K. Asymptomatic malignant pleural effusion: to observe or to manage. J Thorac Dis. 2017;9(Suppl 10):S1146–7.

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(5):1987–2001.

    Article  Google Scholar 

  5. 5.

    Porcel JM, Solé C, Salud A, Bielsa S. Prognosis of cancer with synchronous or metachronous malignant pleural effusion. Lung. 2017;195(6):775–9.

    PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50(5):161–5.

    PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Matthay RA, Coppage L, Shaw C, Filderman AE. Malignancies metastatic to the pleura. Invest Radiol. 1990;25(5):601–19.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  8. 8.

    Interventions for the management of malignant pleural effusions: a network meta‐analysis—Clive, AO—2016|Cochrane Library. [https://www.cochranelibrary.com/cdsr/doi/https://doi.org/10.1002/14651858.CD010529.pub2/full].

  9. 9.

    Bhatnagar R, Kahan BC, Morley AJ, et al. The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. Trials. 2015;16:48.

    PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Boshuizen RC, Vincent AD, van den Heuvel MM. Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion. Support Care Cancer. 2013;21(11):3109–16.

    PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Reddy CB, DeCamp MM, Diekemper RL, et al. Summary for clinicians: clinical practice guideline for management of malignant pleural effusions. Ann ATS. 2018;16(1):17–21.

    Article  Google Scholar 

  12. 12.

    Xia H, Wang X-J, Zhou Q, et al. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS ONE. 2014. https://doi.org/10.1371/journal.pone.0087060.

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32–40.

    PubMed  Article  PubMed Central  Google Scholar 

  14. 14.

    Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. 2004;1:CD002916.

    Google Scholar 

  15. 15.

    Wang L, Deng H, Chen X, et al. Talc pleurodesis versus indwelling pleural catheter among patients with malignant pleural effusion: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2020;18(1):184.

    PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Lee P. Point: should thoracoscopic talc pleurodesis be the first choice management for malignant effusion? Yes CHEST. 2012;142(1):15–7.

    PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Light RW. Counterpoint: should thoracoscopic talc pleurodesis be the first choice management for malignant pleural effusion? No CHEST. 2012;142(1):17–9.

    PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  19. 19.

    Thomas R, Fysh ETH, Smith NA, et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA. 2017;318(19):1903–12.

    PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    Boshuizen RC, Vd Noort V, Burgers JA, et al. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14). Lung Cancer. 2017;108:9–14.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  21. 21.

    Wells G, Shea B, O’Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.

  22. 22.

    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  23. 23.

    Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    PubMed  Article  PubMed Central  Google Scholar 

  24. 24.

    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Mavridis D, Salanti G. How to assess publication bias: funnel plot, trim-and-fill method and selection models. Evid-Based Mental Health. 2014;17(1):30–30.

    Article  Google Scholar 

  26. 26.

    Review Manager (RevMan), Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014.

  27. 27.

    Higgins JPT, Thomas J. Cochrane Handbook for Systematic Reviews of Interventions Version 6 [updated 2019], The Cochrane Collaboration, 2019.

  28. 28.

    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097.

    PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med. 2018;378(14):1313–22.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  30. 30.

    Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma. Eur J Cardiothorac Surg. 2004;26(2):432–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Das SK, Saha SK, Das A, et al. A study of comparison of efficacy and safety of talc and povidone iodine for pleurodesis of malignant pleural effusions. J Indian Med Assoc. 2008;106(9):589–90 ((592)).

    PubMed  Google Scholar 

  32. 32.

    Demmy TL, Gu L, Burkhalter JE, et al. Optimal management of malignant pleural effusions (results of CALGB 30102). J Natl Compr Canc Netw. 2012;10(8):975–82.

    PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Diacon AH, Wyser C, Bolliger CT, et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1445–9.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Fentiman IS, Rubens RD, Hayward JL. Control of pleural effusions in patients with breast cancer. A randomized trial. Cancer. 1983;52(4):737–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  35. 35.

    Fentiman IS, Rubens RD, Hayward JL. A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Eur J Cancer Clin Oncol. 1986;22(9):1079–81.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Haddad FJ, Younes RN, Gross JL, Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. World J Surg. 2004;28(8):749–53 ((discussion 753–754)).

    PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Hamed H, Fentiman IS, Chaudary MA, Rubens RD. Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg. 1989;76(12):1266–7.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Ibrahim IM, Dokhan AL, El-Sessy AA, Eltaweel MF. Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion. J Cardiothorac Surg. 2015;10:64.

    PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Keeratichananont W, Kaewdech A, Keeratichananont S. Efficacy and safety profile of autologous blood versus talc pleurodesis for malignant pleural effusion: a randomized controlled trial. Ther Adv Respir Dis. 2018;12:1753466618816625.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  40. 40.

    Kuzdzał J, Sładek K, Wasowski D, et al. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective, randomized trial. Med Sci Monit. 2003;9(6):PI54-59.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Mohsen TA, Zeid AAA, Meshref M, et al. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg. 2011;40(2):282–6.

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Noppen M, Degreve J, Mignolet M, Vincken W. A prospective, randomised study comparing the efficacy of talc slurry and bleomycin in the treatment of malignant pleural effusions. Acta Clin Belg. 1997;52(5):258–62.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  43. 43.

    Ong KC, Indumathi V, Raghuram J, Ong YY. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology. 2000;5(2):99–103.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  44. 44.

    Paschoalini M da S, Vargas FS, Marchi E et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128(2):684–689.

  45. 45.

    Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118–27.

    PubMed  Article  PubMed Central  Google Scholar 

  46. 46.

    Sørensen PG, Svendsen TL, Enk B. Treatment of malignant pleural effusion with drainage, with and without instillation of talc. Eur J Respir Dis. 1984;65(2):131–5.

    PubMed  PubMed Central  Google Scholar 

  47. 47.

    Zimmer PW, Hill M, Casey K, et al. Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest. 1997;112(2):430–4.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  48. 48.

    Fysh ETH, Waterer GW, Kendall PA, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest. 2012;142(2):394–400.

    PubMed  Article  PubMed Central  Google Scholar 

  49. 49.

    Lynch T, Kalish L, Mentzer S, et al. Optimal therapy of malignant pleural effusions. Int J Oncol. 1996;8(1):183–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Yo SA, Mo EB, El AA, et al. Comparison between thoracoscopic pleurodesis results by talc, doxycycline poudrage, and silver nitrate slurry in patients with malignant pleural effusion. Egypt J Chest Dis Tuberc. 2020;69(1):105.

    Article  Google Scholar 

  51. 51.

    Terra RM, da Costa PB, Dela Vega AJM, Pêgo-Fernandes PM. Adverse events after pleurodesis in patients with malignant pleural effusion. J Thorac Dis. 2020;12(7):3507–13.

    PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Davis JT, Weinstein S. Repair of the pectus deformity: results of the Ravitch approach in the current era. Ann Thorac Surg. 2004;78(2):421–6.

    PubMed  Article  PubMed Central  Google Scholar 

  53. 53.

    Iyer NP, Reddy CB, Wahidi MM, et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions. A systematic review and meta-analysis. Ann Am Thorac Soc. 2019;16(1):124–31.

    PubMed  Article  PubMed Central  Google Scholar 

  54. 54.

    Rodriguez-Panadero F, Montes-Worboys A. Mechanisms of pleurodesis. Respir Int Rev Thorac Dis. 2012;83(2):91–8.

    Google Scholar 

  55. 55.

    Yildirim H, Metintas M, Ak G, et al. Predictors of talc pleurodesis outcome in patients with malignant pleural effusions. Lung Cancer (Amsterdam, Netherlands). 2008;62(1):139–44.

    Article  Google Scholar 

  56. 56.

    Shehata S, Sileem A, El-Fakharany K. Pleural fluid CRP, LDH, and pH as predictors of successful pleurodesis in malignant pleural effusions. Egypt J Chest Dis Tuberc. 2015. https://doi.org/10.1016/j.ejcdt.2015.05.003.

    Article  Google Scholar 

  57. 57.

    Pantazopoulos I, Xanthos T, Vlachos I, et al. Pleural fluid glucose: A predictor of unsuccessful pleurodesis in a preselected cohort of patients with malignant pleural effusion. J BUON. 2014;19(4):1018–23.

    Google Scholar 

  58. 58.

    Rena O, Boldorini R, Papalia E, et al. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma. Ann Thorac Surg. 2015;99(4):1177–83.

    PubMed  Article  PubMed Central  Google Scholar 

  59. 59.

    Hassan M, Gadallah M, Mercer RM, et al. Predictors of outcome of pleurodesis in patients with malignant pleural effusion: a systematic review and meta-analysis. Expert Rev Respir Med. 2020;14(6):645–54.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  60. 60.

    Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev 2007; (2):MR000010.

Download references

Funding

No funding.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Eleftherios T. Beltsios.

Ethics declarations

Conflict of interest

Authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Beltsios, E.T., Mavrovounis, G., Adamou, A. et al. Talc pleurodesis in malignant pleural effusion: a systematic review and meta-analysis. Gen Thorac Cardiovasc Surg (2020). https://doi.org/10.1007/s11748-020-01549-2

Download citation

Keywords

  • Talc pleurodesis
  • Chemical pleurodesis
  • Ipcs
  • Malignant pleural effusions
  • Meta-analysis